NDAINJECTIONINJECTABLE
Approved
Dec 2008
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NEXTERONE (amiodarone hydrochloride) by Baxter International is drug, but it possesses electrophysiologic characteristics of all four vaughan williams classes. First approved in 2008.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXTERONE (amiodarone HCl) is an intravenous antiarrhythmic agent with unique electrophysiologic properties spanning all four Vaughan-Williams classes. It works by blocking sodium, potassium, and calcium channels while exerting noncompetitive antisympathetic effects, effectively slowing conduction and prolonging refractoriness primarily in the AV node. NEXTERONE is used acutely in hospital settings to treat life-threatening ventricular and supraventricular arrhythmias.
Peak6.4 years to LOE
As a peak-stage IV product with strong patent protection through 2033, NEXTERONE maintains steady commercial momentum in the critical care/hospital segment with established sales and medical affairs infrastructure.
Mechanism of Action
drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. One of its main effects, with…
Indications
Worked on NEXTERONE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.